In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin.
AUTOR(ES)
Scully, B E
RESUMO
Cefodizime, an iminomethoxy aminothiazolyl cephalosporin similar to moxalactam and ceftazidime, was less active (minimal inhibitory concentration, 1.6 to 12 micrograms) than cefazolin or cefotaxime against Staphylococcus aureus and Staphylococcus epidermidis. It inhibited Haemophilus and Neisseria spp. at less than 0.5 microgram/ml. It did not inhibit methicillin-resistant staphylococci, enterococci, or Listeria spp. and was 8- to 32-fold less active than cefotaxime, moxalactam, or ceftazidime against Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Providencia spp., and Serratia spp. Cefotaxime-resistant Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris were resistant to cefodizime. Cefodizime was less active than cefoxitin or moxalactam against Bacteroides fragilis. Cefodizime was not hydrolyzed by common plasmid or chromosomal beta-lactamases, and it inhibited type I beta-lactamases.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185001Documentos Relacionados
- In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
- In vitro antibacterial activity and beta-lactamase stability of E-0702, a new cephalosporin.
- In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.
- Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
- In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin.
